Lucinda (Lucy) Bones

Lucy Bones is the Senior Trial Development Manager (STDM) in the Oncology Clinical Trials Office (OCTO) at the University of Oxford. She has worked in clinical research for over 17 years, including 14 years specialising in Clinical Trials of Investigational Medicinal Products (CTIMPs).

Lucy supports researchers in developing new oncology clinical trials, including cancer vaccines, early detection, device, and cancer prevention. She works closely with Chief Investigators, research teams, and collaborators to guide trials through the early development stages - from preparing grant applications and designing study protocols to ensuring that all governance and regulatory requirements are met. She also engages with internal University departments and external stakeholders to support the identification, development, and advancement of new oncology trial opportunities and strategic research partnerships.

Before joining OCTO in 2011, Lucy worked as a Study Coordinator at a commercial research organisation, managing multi-centre clinical trials of over-the-counter medicines and healthcare products. This role was primarily participant-facing and involved overseeing studies conducted both in the United Kingdom and China

OCTO trials currently or previously involved with:

VISTA - Vaccination with ITOP1 in resectable oesophageal adenocarcinoma – Safety, Tolerability and Anti-Tumour activity

LungVax - LungVax: A Phase I Dose-escalation and Phase II Precision-Prevention trial of ChAdOx2-lungvax-NYESO vaccination for patients at risk of new or recurrent non-small cell lung cancer (NSCLC)

EMERALD - Pancreas - Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer

LUD2015-005 - Phase 1/2 Study of anti-PD-L1 in Combination with Chemo(radio)therapy for Oesophageal Cancer

NUTIDE-301 - A two-part, Phase 1 open-label dose escalation and expansion study to assess safety, pharmacokinetics and clinical activity of NUC-3373, a nucleotide analogue, in participants with advanced solid tumours. 

PEMBLA - Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC)

TARDOX - A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin from Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients with Primary or Secondary Liver Tumours

6MP - A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours

CHOP-OR -A study of ofatumumab with CHOP chemotherapy for Richter's syndrome (CHOP-OR)

SONATINA - A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer